Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low ...

Allakos said it plans to explore strategic alternatives, adding that it expects its cash, equivalents and investments will total $35 million to $40 million by the end of June. The company now sports a ...

The California-based company estimates that restructuring activities to close AK006 development will cost around $34 million to $38 million, with a major portion of these payments paid over in the ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

Jefferies, a global investment banking firm, revised its price target for Allakos Inc . (NASDAQ: NASDAQ:ALLK) shares, ...

The San Carlos, Calif., clinical-stage biotechnology company, which ended 2024 with roughly $81 million in cash, equivalents and investments, said it expects to use $34 million to $38 million in cash ...